- TRADE NAME: Lokelma (AstraZeneca)
- INDICATIONS: hyperkalemia
- CLASS: Potassium binder
- FDA APPROVAL DATE: 05/18/2018
- CLINICALLY IMPORTANT, POTENTIALLY HAZARDOUS INTERACTIONS WITH:
None known - PREGNANCY: maternal use is not expected to result in fetal exposure to the drug
Please login to view the rest of this drug profile.
Click on the DRUG REVIEW ARTICLE tab (above) to see a review of sodium zirconium cyclosilicate in the Taylor & Francis journal Expert Opinion on Drug Safety.
(Note that non-subscribers to the journal will only be able to see an abstract of the article.)
Page last updated 08/20/2025
